IGF-1 LR3 and CJC-1295: Interaction Evidence
App Library Tools Pricing Download
[Interaction checker]

IGF-1 LR3 and CJC-1295

Caution · Mechanism only · Reviewed

Short answer: Both raise IGF-1 activity; IGF-1 can lower blood sugar. No human data on IGF-1 LR3.

  • FlagCaution
  • EvidenceMechanism only
  • Sources3
  • Last reviewedOctober 22, 2026

What is known

No human studies of these two together were found. IGF-1 LR3 has no published human studies. CJC-1295 raises the body's own IGF-1, and the approved IGF-1 drug (mecasermin) is labeled for causing low blood sugar. The effects of long-term high IGF-1 in people are not known.

CJC-1295 raised IGF-1 1.5- to 3-fold for 9-11 days after one dose. The tesamorelin (GHRH analog) label says the effects of prolonged high IGF-1 are unknown and recommends IGF-1 monitoring. IGF-1 LR3 is a modified form of IGF-1 and is not the same as mecasermin; how it behaves in people has not been studied.

How strong the evidence is

Mechanism only. Theoretical. No study tested the pair; the concern comes from documented effects of each compound on its own. Caution: There is a documented or likely risk to watch for, such as low blood sugar or added side effects. Talk to your prescriber before combining.

Guides: IGF-1 LR3, CJC-1295. To check this pair alongside others, open it in the peptide interaction checker.

Education only, not medical advice. "No known interaction" means we found nothing reported, not that a combination is safe. Most of the peptides here are not FDA approved, and most pairs have never been studied together in people. Talk to your clinician or pharmacist before you start, stop or combine anything.

Sources

  1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 2006. PMID 16352683
    CJC-1295, a long-acting GHRH analog, raised GH 2- to 10-fold for 6+ days and IGF-1 1.5- to 3-fold for 9-11 days after one injection in healthy adults; half-life 5.8-8.1 days.
  2. INCRELEX (mecasermin) injection - Prescribing Information. FDA label (DailyMed), 2026
    Mecasermin (IGF-1) label: has insulin-like blood-sugar-lowering effects; severe hypoglycemia with seizures has been seen.
  3. EGRIFTA WR (tesamorelin) kit - Prescribing Information. FDA label (DailyMed), 2026
    Tesamorelin label: raises IGF-1, effects of long-term high IGF-1 are unknown; monitor IGF-1. Fluid retention (swelling, joint pain, carpal tunnel) may occur.

Other reviewed pairs with IGF-1 LR3

Other reviewed pairs with CJC-1295